On September 3, 2026, the Endocrine Society issued a statement applauding the introduction in the U.S. House of Representatives of the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act. The Society described the bill as a bipartisan effort intended to address insulin affordability for people with diabetes and to help uninsured patients access this lifesaving medication.
The Society’s announcement framed the INSULIN Act as an important legislative step to protect access to insulin for millions of Americans and emphasized the organization’s willingness to work with both chambers of Congress to advance measures that lower out-of-pocket costs and expand access.
The INSULIN Act was introduced by Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Kim Schrier (D-WA), Rob Bresnahan (R-PA), and Angie Craig (D-MN). The Endocrine Society highlighted the bipartisan nature of the sponsorship in its statement of support.
According to the Society’s description, the INSULIN Act contains multiple measures aimed at reducing financial barriers to insulin:
The article did not reproduce the full legislative text, nor did it report specifics such as eligibility criteria, enforcement mechanisms, or fiscal analysis.
The Endocrine Society underscored the public health urgency that motivates the INSULIN Act. The Society referenced U.S. Centers for Disease Control and Prevention estimates that 38.4 million people—about 11.6% of the U.S. population—have diabetes.
The announcement also cited a 2021 finding that nearly one in five American adults with diabetes—approximately 1.3 million people—reported rationing insulin. The Society used these statistics to reinforce that insulin affordability can be a life-or-death issue for people who rely on insulin daily, including all people with type 1 diabetes and many with type 2 diabetes.
Robert W. Lash, MD, Chief Medical Officer of the Endocrine Society, was quoted in the Society’s release expressing support for the bill sponsors and summarizing the intended benefits: making insulin more affordable for people with private insurance, connecting uninsured patients to resources, and helping ensure that all people who need insulin can obtain it and remain healthy.
The Society repeated the message that no one who depends on insulin should have to choose between purchasing medication and meeting other basic needs.
The INSULIN Act, as described by the Society, aligns with recommendations in the Endocrine Society’s Insulin Access and Affordability Position Statement. That policy document calls for limiting insulin co-pays to no more than $35 per month. The Society framed the bill’s proposed copay cap as consistent with its policy guidance.
The article noted the Society’s intent to engage with both the House and the Senate to advance policies that reflect the Position Statement’s recommendations.
The Endocrine Society stated it looks forward to working with Congress to ensure access to affordable insulin. The source did not report details on committee referrals, timelines for consideration in the House, companion measures beyond mentioning similar Senate legislation, or expected legislative milestones. It likewise did not provide information on projected cost savings, implementation logistics, or whether specific stakeholder groups had endorsed or opposed the bill.
Summary
The Endocrine Society’s September 3, 2026 release endorses the bipartisan INSULIN Act, highlights its principal elements—a $35/month cap for privately insured patients, a resource center and hotline for the uninsured, and promotion of biosimilar competition—and situates the bill within the Society’s existing policy calling for affordable insulin. The Society emphasized the public health imperative, citing CDC diabetes prevalence and the incidence of insulin rationing, and signaled continued advocacy as the bill moves through the legislative process.